BR112022007635A2 - Formulação aquosa e estável de anticorpos - Google Patents
Formulação aquosa e estável de anticorposInfo
- Publication number
- BR112022007635A2 BR112022007635A2 BR112022007635A BR112022007635A BR112022007635A2 BR 112022007635 A2 BR112022007635 A2 BR 112022007635A2 BR 112022007635 A BR112022007635 A BR 112022007635A BR 112022007635 A BR112022007635 A BR 112022007635A BR 112022007635 A2 BR112022007635 A2 BR 112022007635A2
- Authority
- BR
- Brazil
- Prior art keywords
- aqueous
- antibody formulation
- formulation
- stable antibody
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
FORMULAÇÃO AQUOSA E ESTÁVEL DE ANTICORPOS. A presente invenção refere-se ao campo das formulações farmacêuticas de anticorpos. Especificamente, a presente invenção refere-se a uma formulação líquida e estável de anticorpos e a sua preparação farmacêutica e uso. Esta invenção é exemplificada por uma formulação aquosa de um anticorpo anti-inibidor da Via do Fator Tecidual (TFPI).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962934781P | 2019-11-13 | 2019-11-13 | |
US202063081409P | 2020-09-22 | 2020-09-22 | |
PCT/IB2020/060571 WO2021094917A1 (en) | 2019-11-13 | 2020-11-10 | Stable aqueous anti-tfpi antibody formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022007635A2 true BR112022007635A2 (pt) | 2022-07-12 |
Family
ID=73790141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022007635A BR112022007635A2 (pt) | 2019-11-13 | 2020-11-10 | Formulação aquosa e estável de anticorpos |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230035617A1 (pt) |
EP (1) | EP4058061A1 (pt) |
JP (1) | JP2021088548A (pt) |
KR (1) | KR20220100634A (pt) |
CN (1) | CN114786717A (pt) |
AU (1) | AU2020385048A1 (pt) |
BR (1) | BR112022007635A2 (pt) |
CA (1) | CA3160806A1 (pt) |
IL (1) | IL292493A (pt) |
MX (1) | MX2022005836A (pt) |
WO (1) | WO2021094917A1 (pt) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009331570C1 (en) * | 2008-12-22 | 2024-04-18 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
WO2011104381A2 (en) * | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Stable antibody containing compositions |
KR20130086144A (ko) * | 2010-05-28 | 2013-07-31 | 노보 노르디스크 에이/에스 | 항체 및 보존제를 포함하는 안정한 다중-투여 조성물 |
US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US10894083B2 (en) * | 2015-01-28 | 2021-01-19 | Pfizer Inc. | Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation |
BR112018001478A2 (pt) * | 2015-08-19 | 2018-09-18 | Pfizer Inc. | anticorpos do inibidor da via do fator de tecidos e uso dos mesmos |
-
2020
- 2020-11-10 AU AU2020385048A patent/AU2020385048A1/en active Pending
- 2020-11-10 IL IL292493A patent/IL292493A/en unknown
- 2020-11-10 BR BR112022007635A patent/BR112022007635A2/pt unknown
- 2020-11-10 US US17/755,573 patent/US20230035617A1/en active Pending
- 2020-11-10 EP EP20821374.4A patent/EP4058061A1/en active Pending
- 2020-11-10 CA CA3160806A patent/CA3160806A1/en active Pending
- 2020-11-10 CN CN202080079050.7A patent/CN114786717A/zh active Pending
- 2020-11-10 WO PCT/IB2020/060571 patent/WO2021094917A1/en unknown
- 2020-11-10 KR KR1020227019650A patent/KR20220100634A/ko unknown
- 2020-11-10 MX MX2022005836A patent/MX2022005836A/es unknown
- 2020-11-12 JP JP2020188526A patent/JP2021088548A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021094917A1 (en) | 2021-05-20 |
KR20220100634A (ko) | 2022-07-15 |
CN114786717A (zh) | 2022-07-22 |
IL292493A (en) | 2022-06-01 |
JP2021088548A (ja) | 2021-06-10 |
CA3160806A1 (en) | 2021-05-20 |
MX2022005836A (es) | 2022-06-09 |
EP4058061A1 (en) | 2022-09-21 |
US20230035617A1 (en) | 2023-02-02 |
AU2020385048A1 (en) | 2022-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017014376A2 (pt) | formulação aquosa estável de anticorpos antifator de crescimento endotelial vascular (vegf) e uso | |
WO2019171253A8 (en) | Anti-pd-1 antibody compositions | |
BR112017027778A2 (pt) | anticorpos para o fator xi e métodos de uso | |
AR116753A1 (es) | Proceso de preparación de un derivado de pirazolsulfonilamida | |
MX2019010282A (es) | Formulacion de anticuerpos monoclonales. | |
WO2021021837A3 (en) | Anti-pvrig antibodies formulations and uses thereof | |
CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
BR112019010903A2 (pt) | estrutura de cristal de gremlin-1 e anticorpo inibidor | |
BR112019001233A2 (pt) | formulação farmacêutica e uso da mesma | |
CO2021010697A2 (es) | Formulación de anticuerpos terapéuticos | |
BR112021019959A2 (pt) | Anticorpo biespecífico, e, formulação farmacêutica | |
MA48461A (fr) | Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation | |
MA54139A (fr) | Formulation d'anticorps | |
EP3946454A4 (en) | AQUEOUS PHARMACEUTICAL COMPOSITION OF AN ANTI-IL17A ANTIBODY AND ITS USE | |
CL2023000491A1 (es) | Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020). | |
MA53333A (fr) | Formulations pharmaceutiques d'anticorps masqués | |
BR112022026482A2 (pt) | Formulação altamente concentrada de proteínas de ligação ao antígeno do fator xii | |
BR112022007635A2 (pt) | Formulação aquosa e estável de anticorpos | |
MA53466A (fr) | Formulation stable d'anticorps anti-osmr | |
ECSP22092205A (es) | Composición farmacéutica acuosa de levilimab y su uso | |
ECSP21079422A (es) | Método para preparar formulaciones de péptidos estables | |
EP4019047A4 (en) | AQUEOUS PHARMACEUTICAL COMPOSITION OF PROLGOLIMAB ANTI-PD-1 ANTIBODIES AND THEIR USE | |
PL424999A1 (pl) | Farmaceutycznie akceptowalna sól 5-(4-chlorofenylo)-6-etylo-2,4- pirymidynodiaminy | |
MA52122A (fr) | Formulation pharmaceutique pour administration intraduodénale comprenant de la mélévodopa et de la carbidopa | |
IL311811A (en) | Drug formulation of an anti-HLA-DQ2.5 antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: PFIZER INC. (US) |